Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

3.03
-0.1800-5.61%
Post-market: 3.01-0.0200-0.66%17:47 EST
Volume:1.04M
Turnover:3.22M
Market Cap:328.29M
PE:-2.47
High:3.26
Open:3.26
Low:3.03
Close:3.21
52wk High:3.48
52wk Low:1.05
Shares:108.35M
Float Shares:72.65M
Volume Ratio:0.62
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2249
EPS(LYR):-1.7085
ROE:-113.23%
ROA:-22.98%
PB:2.73
PE(LYR):-1.77

Loading ...

Aclaris Therapeutics management to meet with Cantor

TIPRANKS
·
Nov 28

Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million

Reuters
·
Nov 20

Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate

Benzinga
·
Nov 06

Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

Reuters
·
Nov 06

Aclaris Therapeutics reports third quarter 2025 financial results

Reuters
·
Nov 06

BRIEF-Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million

Reuters
·
Nov 06

Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Nov 01

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

GlobeNewswire
·
Oct 29

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS)

TIPRANKS
·
Oct 16

Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Oct 15

Aclaris Therapeutics Hosts R&D Day for Innovations

TIPRANKS
·
Oct 14

Aclaris Therapeutics to host R&D Day on October 14

TIPRANKS
·
Sep 30

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

GlobeNewswire
·
Sep 30

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire
·
Sep 09

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

GlobeNewswire
·
Aug 27

Aclaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Aclaris Therapeutics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $1.777M Beat $1.435M Estimate

Benzinga
·
Aug 07

Aclaris Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Scientific Officer Roland Kolbeck

Reuters
·
Aug 06

Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Aug 01